

Contents

Contributors	vii
1 Introduction	1
David M. Reid and Colin G. Miller	
2 Historical and Current Perspectives on Management of Osteoarthritis and Rheumatoid Arthritis	5
Shirish Dubey and Adewale O. Adebajo	
3 Development of Biological Therapies for Inflammatory Arthritis	37
Neil Basu	
4 Study Design and End Points for Rheumatoid Arthritis Trials	51
Pieter Geusens and Colin G. Miller	
5 Study Design and End Points in Ankylosing Spondylitis Clinical Trials	69
Désirée van der Heijde	
6 Trial Design and Outcomes in Osteoarthritis	81
Nigel Arden	
7 Ethical Considerations	91
Derek Pearson and Colin G. Miller	
8 Organization of the Clinical Trial by the Sponsor	113
Colin G. Miller	
9 Organization of the Trial at the Investigator Site	123
Julie Shotton, David M. Reid, and Colin G. Miller	
10 Role of the Imaging Core Laboratory in Rheumatoid Arthritis and Osteoarthritis Clinical Trials	135
Mark D. Endres and Anna M. Baratelle	
11 Biochemical Markers of Rheumatoid Arthritis and Osteoarthritis: Clinical Utility and Practical Considerations	151
Mario R. Ehlers and Elizabeth T. Leary	

12 Data Analysis and Presentation: Writing a Paper for Publication	171
Derek Pearson	
13 Radiographic Imaging End Points in Rheumatoid Arthritis Trials	201
Anna M. Baratelle and Désirée van der Heijde	
14 Radiography in Clinical Trials Investigating Osteoarthritis	223
Cornelis van Kuijk	
15 Use of Quantitative Magnetic Resonance Imaging in the Cross-Sectional and Longitudinal Evaluation of Structural Changes in Knee Osteoarthritis Patients	235
Jean-Pierre Raynald, Johanne Martel-Pelletier, François Abram, and Jean-Pierre Pelletier	
16 Biochemical Markers as Surrogate End Points of Joint Disease	249
L. Stefan Lohmander and David R. Eyre	
17 Role of Genetics and Genomics in Clinical Trials in Osteoarthritis and Rheumatoid Arthritis	275
Stuart H. Ralston	
18 Cost-Effectiveness of New Biologics for Rheumatoid Arthritis and Osteoarthritis	289
Yolanda Bravo Vergel and David Torgerson	
Abbreviations	309
Index	311